Urogen Pharma (NASDAQ: URGN) recently received a number of ratings updates from brokerages and research firms:

  • 11/15/2017 – Urogen Pharma was downgraded by analysts at UBS AG from an “outperform” rating to a “market perform” rating.
  • 11/15/2017 – Urogen Pharma was downgraded by analysts at Raymond James Financial, Inc. from an “outperform” rating to a “market perform” rating.
  • 11/15/2017 – Urogen Pharma had its “outperform” rating reaffirmed by analysts at CIBC. They now have a $51.00 price target on the stock, up previously from $32.00.
  • 11/15/2017 – Urogen Pharma had its “buy” rating reaffirmed by analysts at Cowen and Company. They wrote, “URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18).””
  • 11/14/2017 – Urogen Pharma was given a new $51.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an “outperform” rating on the stock.
  • 10/18/2017 – Urogen Pharma was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “
  • 10/9/2017 – Urogen Pharma had its price target raised by analysts at Jefferies Group LLC from $27.00 to $37.00. They now have a “buy” rating on the stock.

Shares of Urogen Pharma (NASDAQ:URGN) opened at $41.80 on Tuesday. Urogen Pharma has a one year low of $13.01 and a one year high of $44.63.

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.